In a multicenter, randomized, placebo-controlled dose-finding trial, cagrilintide at doses ranging from 0.3 to 4.5 mg weekly produced dose-dependent weight reductions, with the 4.5 mg dose achieving approximately 10.8% weight loss at 26 weeks compared to 3.0% with placebo
Use in pregnancy is not recommended unless the potential benefit justifies the potential risk to the fetus
However, no significant intervention effect was found on any EF scores
The results showed that leukemia cells presented a higher expression of most CPT isoforms, including CPT2
It is important to note that while these branded medications are FDA-approved for specific uses, many individuals access treatment through a personalized program
G (00:15:20): We're going to get to some people you know I think